

Certificate of Analysis for NR-51520

Pseudomonas aeruginosa, Strain MRSN 1344

Catalog No. NR-51520

This reagent is the tangible property of the U.S. Government.

Product Description:

Pseudomonas aeruginosa (P. aeruginosa), strain MRSN 1344 was isolated in 2010 from a human groin as part of a surveillance program in the United States. P. aeruginosa, strain MRSN 1344 was deposited as sensitive to amikacin, aztreonam, ceftazidime, gentamicin, imipenem, meropenem, piperacillin/tazobactam and tobramycin, intermediately resistant to cefepime and resistant to ciprofloxacin and levofloxacin.

Lot: 70024594¹ Manufacturing Date: 11APR2019

TEST	SPECIFICATIONS	RESULTS
Phenotypic Analysis		
Cellular morphology	Gram-negative rods	Gram-negative rods
Colony morphology ²	Report results	Circular, low convex, entire, smooth and cream (Figure 1)
Motility (wet mount)	Report results	Motile
VITEK [®] 2 (GN card)	P. aeruginosa (≥ 89%)	P. aeruginosa (99%)
Antibiotic Susceptibility Profile ³ VITEK [®] (AST-GN81 Card) Ampicillin	Report results	Resistant (≥ 32 μg/mL)
Amoxicillin/clavulanic acid	Report results	Resistant (≥ 32 µg/mL)
Piperacillin/tazobactam	Sensitive	Sensitive (8 µg/mL)
Cefazolin	Report results	Resistant (≥ 64 µg/mL)
Cefoxitin	Report results	Resistant (≥ 64 µg/mL)
Ceftazidime	Sensitive	Sensitive (2 µg/mL)
Ceftriaxone	Report results	Sensitive (8 µg/mL)
Cefepime	Intermediate	Sensitive (8 µg/mL) ⁴
Meropenem	Sensitive	Sensitive (≤ 0.25 µg/mL)
Amikacin	Sensitive	Sensitive (≤ 2 µg/mL)
Gentamicin	Sensitive	Sensitive (≤ 1 µg/mL)
Tobramycin	Sensitive	Sensitive (≤ 1 µg/mL)
Ciprofloxacin	Resistant	Intermediate (2 µg/mL) ⁵
Levofloxacin	Resistant	Intermediate (4 µg/mL) ⁶
Tetracycline	Report results	Resistant (≥ 16 µg/mL)
Nitrofurantoin	Report results	Resistant (≥ 512 µg/mL)
Trimethoprim/sulfamethoxazole	Report results	≥ 160 µg/mL ⁷
Genotypic Analysis		
Sequencing of 16S ribosomal RNA gene (1460 base pairs)	≥ 99% sequence identity to P. aeruginosa, strain MRSN 1344 (GenBank: RXWG01000136.1)	100% sequence identity to <i>P. aeruginosa,</i> strain MRSN 1344 (GenBank: RXWG01000136.1)
Purity (post-freeze) ⁸	Growth consistent with expected colony morphology	Growth consistent with expected colony morphology
Viability (post-freeze) ²	Growth	Growth

¹NR-51520 was produced by inoculation of the depositor material into Tryptic Soy broth and grown for 1 day at 37°C in an aerobic atmosphere. Broth inoculum was added to Tryptic Soy agar kolles, which were grown for 1 day at 37°C in an aerobic atmosphere to produce this lot.

BEI Resources www.beiresources.org E-mail: contact@beiresources.org

Tel: 800-359-7370 Fax: 703-365-2898

²1 day at 37°C in an aerobic atmosphere on Tryptic Soy agar

³Minimum Inhibitory Concentration (MIC); MIC Interpretation Guideline: CLSI M100-S28 (2018)

⁴Susceptibilty results for this antibiotic is within one doubling dilution of specification, which is considered an equivalent result.

⁵P. aeruginosa, strain MRSN 1344 was deposited as resistant to ciprofloxacin. Repeated antibiotic susceptibility testing determined that strain MRSN 1344 is intermediately resistant to ciprofloxacin.




SUPPORTING INFECTIOUS DISEASE RESEARCH

Certificate of Analysis for NR-51520

⁶P. aeruginosa, strain MRSN 1344 was deposited as resistant to levofloxacin. Repeated antibiotic susceptibility testing determined that strain MRSN 1344 is intermediately resistant to levofloxacin.

⁸Purity of this lot was assessed for 7 days at 37°C in an aerobic atmosphere with and without 5% CO₂ on Tryptic Soy agar.





/Heather Couch/ Heather Couch

18 NOV 2019

Program Manager or designee, ATCC Federal Solutions

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

ATCC® is a trademark of the American Type Culture Collection.

You are authorized to use this product for research use only. It is not intended for human use.

BEI Resources www.beiresources.org E-mail: contact@beiresources.org

Tel: 800-359-7370 Fax: 703-365-2898

⁷Trimethoprim/sulfamethoxazole MIC interpretive standards are not available for *P. aeruginosa*, however most clinical isolates are resistant to trimethoprim/sulfamethoxazole. For more information, please refer to Köhler, T., et al. "Multidrug Efflux in Intrinsic Resistance to Trimethoprim and Sulfamethoxazole in *Pseudomonas aeruginosa.*" <u>Antimicrob. Agents Chemother.</u> 40 (1996): 2288-2290. PubMed: 9036831.